Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.86 |
| ▸ | HPGD | P15428 | 6/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL106485 | 0.98 | KDM4E (0.91) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL27610516 | 0.98 | KDM4E (0.91) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL28007731 | 0.95 | KDM4E (0.86) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL503979 | 0.95 | KDM4E (0.86) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL7160601 | 0.95 | KDM4E (0.86) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL6249450 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL31140000 | 0.93 | HPGD (0.83) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL27974441 | 0.93 | HPGD (0.83) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL10669448 | 0.93 | HPGD (0.83) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL455422 | 0.93 | KDM4E (1.00) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855242-B2 | Dental resin composition, method of manufacture, and method of use thereof | PENTRON CLINICAL TECHNOLOGIES LLC (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070049656-A1 | DENTAL RESIN COMPOSITION, METHOD OF MANUFACTURE, AND METHOD OF USE THEREOF | PENTRON CLINICAL TECHNOLOGIES, INC (US) | 2007-03-01 | — | — | US | disclosed |
| US-4240832-A | CALCIUM HYDROXIDE WITH CONDENSATE OF A SALICYLATE ESTER AND AN ALDEHYDE | SYBRON CORPORATION (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049656-A1 | DENTAL RESIN COMPOSITION, METHOD OF MANUFACTURE, AND METHOD OF USE THEREOF | CAD, MMAB, DNMT3A | KDM4E 495/4885HPGD 799/4885ALDH1A1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.